Biodel
Biodel was a Danbury, Connecticut-based biopharmaceutical company developing therapeutics for diabetes treatment, founded in 2003 and previously listed on NASDAQ as BIOD before delisting; the entity now appears dormant with no active web presence.
- Company typePrivate
- Founded2003
- HeadquartersDanbury, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biodel does
Biodel was a biopharmaceutical company developing and commercializing therapeutics for the treatment of diabetes. Founded in 2003 and headquartered in Danbury, Connecticut, the company was previously publicly traded on NASDAQ under the ticker symbol BIOD before being delisted. Biodel's strategic focus, as captured in its short description, was on diabetes therapeutics — an indication area requiring complex clinical development and regulatory pathways typical of small-molecule or biologic drug programs.
The company raised approximately $48.5M across two recorded financing rounds in 2011 and 2012, with participation from healthcare-specialist investors Great Point Partners and OrbiMed. Solomon S. Steiner, who co-founded the company and served as CEO and Chairman, anchored the leadership team alongside Ira W. Lieberman as Chairman of the Board. Headcount was reported in the 11–50 range, consistent with a small clinical-stage biotech.
The input data contains no specifics on Biodel's products, pipeline assets, technology platform, manufacturing capabilities, partnerships, customer segments, or revenue model. The company's website (biodel.com) currently resolves to a generic GoDaddy BrandPortal template page rather than an operational corporate site, and the company is listed as delisted. Taken together, the available evidence — delisted status, inactive web presence, no post-2012 funding or product activity, and absence of any current operational data — strongly indicates that Biodel is no longer an actively operating business and should be treated as a dormant or wound-down entity for investment-analysis purposes.
Biodel firmographics
Firmographics- Name
- Biodel
- Legal name
- BrandPortal
- Website
- https://biodel.com
- Company type
- Private
- Founded year
- 2003
- Headcount range
- 1–10 employees
- Short description
- Biodel was a Danbury, Connecticut-based biopharmaceutical company developing therapeutics for diabetes treatment, founded in 2003 and previously listed on NASDAQ as BIOD before delisting; the entity now appears dormant with no active web presence.
- Ownership category
- akta.pro rank
Biodel industry classification
Industry- Product category
- Diabetes Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Insulin & Analog Biosimilars (HLAIAFAB), Insulin & Analog Biosimilars (HLAAAHAD)
Keywords
Where Biodel is headquartered
LocationHeadquarters
- HQ city
- Danbury
- HQ country
- United States
- HQ region
- North America
Markets served
Biodel business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Biodel product offering
Product offeringCore offering
Biodel is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of diabetes. The firm operates in the specialty pharmaceutical space, focused on therapeutic candidates targeting diabetes patients. Based in Danbury, Connecticut, the company was founded in 2003 and has historically been publicly traded on NASDAQ under the ticker BIOD.
Differentiator
Problem solved
Functional benefit
Products and services
- Diabetes therapeutics program Diabetes therapeutics are Biodel's core development and commercialization focus, intended for healthcare providers and patients with diabetes.
Companies that use Biodel
Customer profileIdeal customer profiles1 record
Biodel technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Biodel partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights2 records
Biodel competitors and assessment
Company assessmentDirect peers
- Intarcia Therapeutics: Developer of an implantable osmotic pump for chronic delivery of diabetes and other therapies. Comparable as a small, specialty diabetes drug-delivery company pursuing novel mechanism/formulation approaches.
- vTv Therapeutics: Clinical-stage developer of small-molecule therapies including candidates for type 1 diabetes. Comparable as a small-cap, pipeline-focused diabetes therapeutics company competing for capital and partnerships.
- Zealand Pharma: Peptide-based therapeutics company with diabetes and metabolic disease programs (including collaboration with Sanofi on GLP-1 agonists). Comparable in diabetes therapeutic focus and partnership-driven development model.
- Dance Biopharm (now Aerami Therapeutics): Developer of inhaled insulin therapy (Dance 501 / Afrezza-adjacent technology). Directly comparable as a small diabetes therapeutics company competing with established injectable insulin franchises.
- MannKind Corporation: Specialty biopharma focused on inhaled insulin (Afrezza) for diabetes. Directly comparable as a small-cap diabetes therapeutics developer that has navigated commercialization against incumbent insulin manufacturers.
Broad incumbents
- AstraZeneca: Diabetes incumbent through Bydureon (exenatide) and Farxiga (dapagliflozin). Comparable as a broad incumbent with both injectable and oral diabetes franchises that new entrants must clinically differentiate against.
- Sanofi: Diabetes incumbent with Lantus, Toujeo, and other insulin products, plus partnership with Zealand Pharma on GLP-1. Comparable as a diversified pharma whose diabetes franchise influences pricing and access for specialty entrants.
- Eli Lilly: Major diabetes incumbent with Humalog, Trulicity, Mounjaro, and other insulin/GLP-1 franchises. Comparable as a broad incumbent whose cardiometabolic pipeline and commercial scale set the competitive standard for new entrants.
- Merck: Diversified pharma with the Januvia/Janumet DPP-4 diabetes franchise. Comparable as a broad incumbent whose oral and combination diabetes products define the standard-of-care landscape for new therapies.
- Novo Nordisk: Global leader in diabetes care with the dominant insulin franchise and GLP-1 portfolio (Ozempic, Wegovy). Comparable as the benchmark incumbent against which any diabetes therapeutic ultimately competes for formulary access and prescriber share.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Biodel social profiles
Digital presenceBiodel financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biodel leadership team
Management profileNumber of profiles
Profiles2 records
Biodel funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biodel M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biodel
What does Biodel do?
Biodel is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of diabetes. The firm operates in the specialty pharmaceutical space, focused on therapeutic candidates targeting diabetes patients. Based in Danbury, Connecticut, the company was founded in 2003 and has historically been publicly traded on NASDAQ under the ticker BIOD.
When was Biodel founded?
Biodel was founded in 2003. It employs 1 to 10 people.
Where is Biodel based?
Biodel is headquartered in Danbury, United States, in the North America region.
Who are Biodel's main competitors?
Direct peers on record are Intarcia Therapeutics, vTv Therapeutics, Zealand Pharma, Dance Biopharm (now Aerami Therapeutics) and MannKind Corporation. Broad incumbents are AstraZeneca, Sanofi, Eli Lilly, Merck and Novo Nordisk.
Does Biodel have an API?
No public API is recorded for Biodel.
What industry is Biodel in?
Biodel's product category is Diabetes Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAFAB, Insulin & Analog Biosimilars. Its NAICS code is 325414 and its SIC code is 2834.